Elepsia Xr 1500 Mg Tablet, Extended Release
NDC Package 80705-101-99
Package Information
Elepsia Xr 1500 Mg (levetiracetam) tablets is levetiracetam is used to treat seizures (epilepsy). This formulation utilizes a tablet, extended release delivery system. Marketed by Tripoint Therapeutics, Llc, this product is identified by NDC 80705-101 and is authorized under FDA application NDA204417.
Identification & Billing
- RxCUI: 1605362 - levETIRAcetam 1000 MG 24HR Extended Release Oral Tablet
- RxCUI: 1605362 - 24 HR levetiracetam 1000 MG Extended Release Oral Tablet
- RxCUI: 1605362 - levetiracetam 1000 MG 24 HR Extended Release Oral Tablet
- RxCUI: 1605368 - Elepsia XR 1000 MG 24HR Extended Release Oral Tablet
- RxCUI: 1605368 - 24 HR levetiracetam 1000 MG Extended Release Oral Tablet [Elepsia]
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 80705 - Tripoint Therapeutics, Llc
- 80705-101 - Elepsia Xr 1500 Mg
- 80705-101-99 - 1 BLISTER PACK in 1 CARTON / 7 TABLET, EXTENDED RELEASE in 1 BLISTER PACK
- 80705-101 - Elepsia Xr 1500 Mg
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (80705-101). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 80705-101-99 identifies a specific commercial package of 1 blister pack in 1 carton / 7 tablet, extended release in 1 blister pack of Elepsia Xr 1500 Mg, a human prescription drug labeled by Tripoint Therapeutics, Llc. This tablet, extended release is formulated for oral use and contains levetiracetam as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Tripoint Therapeutics, Llc on February 12, 2021. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
Levetiracetam is used to treat seizures (epilepsy). It belongs to a class of drugs known as anticonvulsants. Levetiracetam may decrease the number of seizures you have.
How is this Tripoint Therapeutics, Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 80705010199. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.